VIDEO: Duravyu for wet AMD shows similar outcomes to aflibercept

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert.

According to Ribeiro, in the DAVIO 2 trial, Duravyu for wet age-related macular degeneration showed similar outcomes in best corrected visual acuity and central subfield thickness compared with aflibercept.

He also touched upon upcoming phase 3 trials for Duravyu.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures:
Ribeiro reports being chief medical officer at EyePoint Pharmaceuticals.

Read more about

This post was originally published on this site